These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 19913350

  • 1. Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies.
    Schröder FH, van den Bergh RC, Wolters T, van Leeuwen PJ, Bangma CH, van der Kwast TH, Roobol MJ.
    Eur Urol; 2010 Feb; 57(2):256-66. PubMed ID: 19913350
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
    Schröder FH, Bangma CH, Roobol MJ.
    Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
    [Abstract] [Full Text] [Related]

  • 4. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
    Zhu X, van Leeuwen PJ, Bul M, Otto SJ, de Koning HJ, Bangma CH, Schröder FH, Roobol MJ.
    Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
    [Abstract] [Full Text] [Related]

  • 5. Screening: should more biopsies be taken in larger prostates?
    van Leeuwen P, van den Bergh R, Wolters T, Schröder F, Roobol M.
    BJU Int; 2009 Oct; 104(7):919-24. PubMed ID: 19466943
    [Abstract] [Full Text] [Related]

  • 6. Atrophy in prostate needle biopsy cores and its relationship to prostate cancer incidence in screened men.
    Postma R, Schröder FH, van der Kwast TH.
    Urology; 2005 Apr; 65(4):745-9. PubMed ID: 15833520
    [Abstract] [Full Text] [Related]

  • 7. A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam.
    Roobol MJ, Zhu X, Schröder FH, van Leenders GJ, van Schaik RH, Bangma CH, Steyerberg EW.
    Eur Urol; 2013 Apr; 63(4):627-33. PubMed ID: 22841675
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Features of prostate cancers detected during a prevalence screening round. The Rotterdam experience.
    Van der Kwast TH, Postma R, Hoedemaeker RF, van Leenders GJ, Schröder FH.
    Can J Urol; 2005 Jun; 12 Suppl 2():16-20. PubMed ID: 16018827
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prostate biopsy: who, how and when. An update.
    Djavan B, Milani S, Remzi M.
    Can J Urol; 2005 Feb; 12 Suppl 1():44-8; discussion 99-100. PubMed ID: 15780165
    [Abstract] [Full Text] [Related]

  • 13. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ, Kranse R, de Koning HJ, Schröder FH.
    Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [Abstract] [Full Text] [Related]

  • 14. Towards an optimal interval for prostate cancer screening.
    van Leeuwen PJ, Roobol MJ, Kranse R, Zappa M, Carlsson S, Bul M, Zhu X, Bangma CH, Schröder FH, Hugosson J.
    Eur Urol; 2012 Jan; 61(1):171-6. PubMed ID: 21840117
    [Abstract] [Full Text] [Related]

  • 15. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Raaijmakers R, Wildhagen MF, Ito K, Pàez A, de Vries SH, Roobol MJ, Schröder FH.
    Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
    [Abstract] [Full Text] [Related]

  • 16. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening.
    Postma R, Schröder FH, van Leenders GJ, Hoedemaeker RF, Vis AN, Roobol MJ, van der Kwast TH.
    Eur Urol; 2007 Jul; 52(1):89-97. PubMed ID: 17257742
    [Abstract] [Full Text] [Related]

  • 17. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam.
    Gosselaar C, Roobol MJ, Roemeling S, Schröder FH.
    Eur Urol; 2008 Sep; 54(3):581-8. PubMed ID: 18423977
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam.
    van der Cruijsen-Koeter IW, Roobol MJ, Wildhagen MF, van der Kwast TH, Kirkels WJ, Schröder FH.
    Urology; 2006 Sep; 68(3):615-20. PubMed ID: 17010732
    [Abstract] [Full Text] [Related]

  • 20. Post-treatment prostate biopsies in the era of three-dimensional conformal radiotherapy: what can they teach us?
    Zapatero A, Mínguez R, Nieto S, Martín de Vidales C, García-Vicente F.
    Eur Urol; 2009 Apr; 55(4):902-9. PubMed ID: 18485578
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.